LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Home・Aandelen Lijst・AbCellera Biologics Inc

AbCellera Biologics Inc

Gesloten

SectorGezondheidszorg

3.51

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.44

Max

3.58

Belangrijke statistieken
By Trading Economics
Inkomsten	48M -8.9M
Verkoop	36M 45M
Winstmarge	-19.942
Werknemers	562
EBITDA	22M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+97.18% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	172M 1.1B
Vorige openingsprijs	3.51
Vorige sluitingsprijs	3.51

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.99 / 2.635 Steun & Weerstand

AbCellera Biologics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mrt 2026, 22:51 UTC

Winsten

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mrt 2026, 21:40 UTC

Acquisities, Fusies, Overnames

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mrt 2026, 20:31 UTC

Winsten

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mrt 2026, 23:49 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mrt 2026, 23:31 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery -- Market Talk

18 mrt 2026, 22:49 UTC

Marktinformatie

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mrt 2026, 22:41 UTC

Marktinformatie

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mrt 2026, 22:36 UTC

Winsten

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mrt 2026, 22:24 UTC

Winsten

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mrt 2026, 22:23 UTC

Winsten

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mrt 2026, 22:23 UTC

Winsten

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mrt 2026, 21:58 UTC

Winsten

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mrt 2026, 21:55 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

18 mrt 2026, 21:55 UTC

Marktinformatie

Winsten

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mrt 2026, 21:40 UTC

Marktinformatie

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mrt 2026, 21:16 UTC

Marktinformatie

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mrt 2026, 21:00 UTC

Belangrijke Nieuwsgebeurtenissen

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mrt 2026, 20:58 UTC

Winsten

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mrt 2026, 20:41 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:29 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:25 UTC

Winsten

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mrt 2026, 20:17 UTC

Winsten

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mrt 2026, 20:14 UTC

Marktinformatie

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mrt 2026, 20:09 UTC

Winsten

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mrt 2026, 20:07 UTC

Winsten

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mrt 2026, 20:06 UTC

Winsten

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mrt 2026, 20:04 UTC

Winsten

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mrt 2026, 20:03 UTC

Winsten

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Peer Vergelijking

Prijswijziging

AbCellera Biologics Inc Prognose

Koersdoel

By TipRanks

97.18% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7 USD 97.18%

Hoogste 7 USD

Laagste 7 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor AbCellera Biologics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan AbCellera Biologics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.99 / 2.635Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.